首页> Molecular therapy : the journal of the American Society of Gene Therapy> Neo-antigen tumor vaccination depends on CD4-licensing conveyed by adeno-associated virus like particles.

Neo-antigen tumor vaccination depends on CD4-licensing conveyed by adeno-associated virus like particles.

导出 OA

翻译打印收藏纠错

第一作者： Lasse,Neukirch

第一单位： Clinical Cooperation Unit "Applied Tumor Immunity", German Cancer Research Center (DKFZ), Im Neuenheimer Feld 460, Heidelberg, Germany.

作者： Lasse,Neukirch ^[1] ; Silke,Uhrig-Schmidt ^[1] ; Katharina,von Werthern ^[1] ; Alexandra,Tuch ^[1] ; Joscha A,Kraske ^[2] ; Yanhong,Lyu ^[1] ; Benedicte,Lenoir ^[1] ; Stefan B,Eichmüller ^[3] ; Marten,Meyer ^[1] ; Inka,Zörnig ^[2] ; Dirk,Jäger ^[4] ; Patrick,Schmidt ^[5]

作者单位： Clinical Cooperation Unit "Applied Tumor Immunity", German Cancer Research Center (DKFZ), Im Neuenheimer Feld 460, Heidelberg, Germany. ^[1] Department of Medical Oncology, National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Im Neuenheimer Feld 460, Heidelberg, Germany. ^[2] GMP and T Cell Therapy Group, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, Germany. ^[3] Clinical Cooperation Unit "Applied Tumor Immunity", German Cancer Research Center (DKFZ), Im Neuenheimer Feld 460, Heidelberg, Germany; Department of Medical Oncology, National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Im Neuenheimer Feld 460, Heidelberg, Germany. ^[4] Department of Medical Oncology, National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Im Neuenheimer Feld 460, Heidelberg, Germany; GMP and T Cell Therapy Group, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, Germany. Electronic address: patrick.schmidt@nct-heidelberg.de. ^[5]

关键词 AAVLP CD4 licensing immunotherapy neo-antigen vaccine